We are live on ! Find out more
MGX icon

Metagenomi Therapeutics
MGX

79 hedge funds and large institutions have $13.5M invested in Metagenomi Therapeutics in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 20

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

3% more funds holding

Funds holding: 77 → 79 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.53% less ownership

Funds ownership: 28.71% → 26.18% (-2.5%)

65% less capital invested

Capital invested by funds: $38.8M → $13.5M (-$25.2M)

Holders
79
Holders Change
+2
Holders Change %
+2.6%
% of All Funds
1.06%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
28
Reduced
20
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$450K
2
Millennium Management
Millennium Management
New York
+$407K
3
State Street
State Street
Massachusetts
+$326K
4
TCM
Tang Capital Management
California
+$322K
5
BlackRock
BlackRock
New York
+$236K

Top Sellers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
-$1.49M
2
Morgan Stanley
Morgan Stanley
New York
-$1.39M
3
Citadel Advisors
Citadel Advisors
Florida
-$540K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$422K
5
Norges Bank
Norges Bank
Norway
-$257K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$2.1M +$236K +99,125 +7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.98M +$450K +188,798 +15%
PHS
3
PFM Health Sciences
California
$1.2M – – –
SVGI
4
Sozo Ventures GP II
California
$1.01M – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$843K +$76.6K +32,153 +5%
State Street
6
State Street
Massachusetts
$771K +$326K +137,023 +32%
CCM
7
Catalio Capital Management
New York
$719K – – –
PLC
8
Peapod Lane Capital
New York
$479K +$2.96K +1,244 +0.4%
PVI
9
Pura Vida Investments
New York
$360K – – –
Norges Bank
10
Norges Bank
Norway
$343K -$257K -107,892 -30%
Northern Trust
11
Northern Trust
Illinois
$297K -$12.8K -5,384 -2%
Morgan Stanley
12
Morgan Stanley
New York
$264K -$1.39M -582,033 -75%
Millennium Management
13
Millennium Management
New York
$252K +$407K +170,699 +1,185%
HA
14
HHLR Advisors
Cayman Islands
$205K -$1.49M -627,069 -81%
TCM
15
Tang Capital Management
California
$184K +$322K +134,978 New
Wells Fargo
16
Wells Fargo
California
$150K +$35.2K +14,780 +16%
GLA
17
Good Life Advisors
Pennsylvania
$136K -$59.6K -25,000 -20%
Renaissance Technologies
18
Renaissance Technologies
New York
$135K -$129K -54,200 -35%
BCM
19
Bridgeway Capital Management
Texas
$134K +$15.5K +6,500 +7%
RA
20
Resolute Advisors
California
$122K – – –
AQR Capital Management
21
AQR Capital Management
Connecticut
$119K +$209K +87,719 New
Goldman Sachs
22
Goldman Sachs
New York
$109K -$222K -93,320 -54%
Verition Fund Management
23
Verition Fund Management
Connecticut
$98.1K +$46K +19,290 +37%
UBS Group
24
UBS Group
Switzerland
$92.1K +$68.4K +28,701 +73%
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$90K – – –
1
2 3 4

MGX Hedge Fund Activity: Q1 2025 in Review

79 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q1 2025, worth a combined $13.5M — down 65% from $38.8M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new MGX positions and 8 closed out — a net gain of 2 holders — while 28 added to existing stakes and 20 trimmed.

The largest buyer was Vanguard Group, adding an estimated $450K. The largest seller was HHLR Advisors, cutting an estimated $1.49M.

  • 79 institutional investors held Metagenomi Therapeutics (MGX) as of Q1 2025, up from 77 in Q4 2024.
  • Funds reported $13.5M of Metagenomi Therapeutics stock for Q1 2025, down 65% quarter-over-quarter.
  • 10 funds opened new Metagenomi Therapeutics positions in Q1 2025 and 8 closed out, a net change of +2 holders.
  • The largest Metagenomi Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $450K added.
  • The largest Metagenomi Therapeutics seller in Q1 2025 was HHLR Advisors, an estimated $1.49M sold.

Based on aggregated 13F filings for Q1 2025.